A Healthcare Debate: Progyny vs. Hims & Hers

In this podcast, Motley Fool analysts Alicia Alfiere, Sanmeet Deo, and Tim Beyers discuss:

• Progyny vs. Hims & Hers -- which goes on the watch list?
• Intel and Nvidia's big $5 billion deal.
• Reflections on Rule Breaker investing.

To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10 list of stocks to buy.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

A full transcript is below.

Should you invest $1,000 in Hims & Hers Health right now?

Before you buy stock in Hims & Hers Health, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $649,280!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,084,802!*

Now, it’s worth noting Stock Advisor’s total average return is 1,058% — a market-crushing outperformance compared to 189% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 22, 2025

This podcast was recorded on Sept. 22, 2025.

Tim Beyers: Which is the better healthcare breaker? Progeny or Hims & Hers? Welcome to Motley Fool Money. Good morning. I am. Your host Tim Byers with me are two of my favorite Fools, Sanmeet Deo and Alicia Alfiere from the Rule Breakers team. We're going to do a small debate here. The way this is going to work, Fools is that I am going to ask you to make your case first for Progeny, then for Hims & Hers. I'm going to ask you a follow up question, each of you. Then I'm going to make a call on which one is going on my watch list. The audience is your audience, but also I am your audience. So you got to convince me. Alicia, make the case. Why do I want to be invested in Progeny?

Alicia Alfiere: Okay, so Progeny is essentially a health benefit that employers provide as part of their overall benefits package. Think of it like a super customer focused health benefit, including drug coverage for fertility and family building. So infertility is a migraine level problem that roughly one in six people of reproductive age experience. It's also an expensive problem. So depending on where you live, a single round of IVF can cost 10-$20,000 or more, and that might not even include medication. Prior to companies like progeny, if fertility services were covered by insurance, it could be restrictive with lifetime dollar maximums and things like mandated step therapy, which was expensive, wasted time and wasn't a personalized approach. So, of the six signs of a rule Breaker, Progeny has about we'll say 3.5. The most important part, I think, is their sustainable advantage. [laughs] They have a strong brand power and an excellent network with great clinical outcomes. They have a strong brand in their core market. They're expanding into services like pregnancy support and menopause care. It also has an impressive network of fertility specialists across the US that really deliver impressive results by harnessing expertise and data. So for example, within Progeny's network, there's a 21% lower miscarriage rate, a 23% higher live birth rate, and it takes 1.5 fewer retrievals per live birth. So better results, more efficient, and as a result, less costly.

Tim Beyers: So this is a much better suite of services for those who are dealing with infertility. This is essentially the argument for Progeny is if you just go for in vitro fertilization, without the aid of Progeny, your outcomes might not be as good. Single follow up question for you here. They work with providers, and they don't necessarily work with insurers here. They work with companies that provide this benefit, and they do have some customer concentration, Alicia, and they've lost some customers, some big customers. So how can this company grow sustainably, despite how good the outcomes are based on their data?

Alicia Alfiere: This is an excellent question. So they did lose one major customer last year, and it did impact the company's revenue, something like 12-13%. Now, they do have over 500 clients, so they could continue to grow by continuing to grow the number of clients that they serve and the number of covered lives or the people that are covered under their services. They can also do more optionality. So I mentioned they expanded into menopause care and pregnancy services, so they can continue to grow in their optionality for different women's care services.

Tim Beyers: Sanmeet. So, ticker for Progeny, PGNY. That's Progeny. We're moving over to Hims & Hers, ticker HIMS. Give it to me. Why do I want this one?

Sanmeet Deo: Hims & Hers is really exactly the kind of rule breaking platform company I look for personally. It's delivering rapid growth, recurring revenue, improving margins, it has a relentless expansion into huge new markets. They're not just writing a trend. They're building a modern healthcare brand for the next generation with technology and customer experience at the core. So there's several factors here. First is their breakneck growth. They've been growing 40% year over year in a healthcare sector, which is quite fast, and all of it's being driven by customer acquisition and high retention rates. They have recurring revenue because the customers they get are paying subscriptions for the products and services that they get. Another appealing aspect is they have a strong consumer appeal brand and user experience. They're attracting a lot of the millennials and Gen Z who don't want to go into doctor's office, especially for stigma type conditions. They're meeting those customers online, on phones, so they can get treatments for things like mental health, hair loss, weight management, and now they're expanding into even things like hormonal healthcare.

Don't forget the Hers brand, which will also be doing some menopause treatments in the future. So I think also Hims has a massive addressable market opportunity. I mean, and optionality. I mean, they're in already multiple areas that could develop into billion dollar brands when it comes to some of the things that I talked about before, but they've also been scaling. They just launched into men's hormones. They're looking into female menopause, also looking at longevity. Those are all on their radar to expand into. Finally, the biggest thing is technology and profitability. They're bringing technology into healthcare where it's severely lacked, and it's difficult. It's not easy by any means, but they've created a platform that has been easy use. Now they're just at that inflection point of profitability. Their earnings profitable in the past fiscal year, and they're looking to expand on that.

Tim Beyers: I mean, you mentioned the technology piece of this. A lot of this interaction with the Hims & Hers brand is via mobile app. We are seeing this in other places. So it's not like that's completely novel, but I do can see that that is interesting. But you mentioned something about, I mean, Sanmeet you said, we're getting into the hormone business. That sounds like the FDA might have something to say about that. Can we talk about regulatory risk here? Like, what's going on here? How do they deal with regulators?

Sanmeet Deo: I mean, absolutely, regulatory risk is probably one of the biggest risk factors in this company. You don't want to you don't want to wake up the next morning holding your hem stock and see some big thing come down from the government. They're doing the things that they need to do to keep that manageable. They have a robust compliance team. They've hired former regulators on their team to keep them in compliance with some regulators laws. They've been, from what I've seen, also, very quick to make changes and adjustments to their platform to their products when it seems like the federal government or the FDA is clamping down on them. They bought facilities that are within compliance and also they're doing the things that they need to do to stay in the good graces.

Tim Beyers: I mean, it's interesting. So Fools, we want to hear from you. Which of these two do you want on your watch list? I'm going to tell you right now that my choice for this is Progeny. The reason why Sanmeet, is because that regulatory risk feels pretty existential to me and we have an activist federal government right now. Without making this political in any way, this government has decided to make big sweeping moves faster than anybody anticipated. That for Hims & Hers, that could be significant in ways that I can't predict. But I like both of these, and I think you both have made a compelling argument for why they are potential breakers in the making. But Fools, we want to know what you think. Get your comments in. Let us know what you want. If you have a strong case for Hims & Hers, let's hear it. Back them up. Just because I back Progeny doesn't mean I'm right. So let's hear about it. Up next. Intel and NVIDIA. Get cuddly. How should investors respond to this deal between these two? You're listening to Motley Fool Money.

ADVERTISEMENT: Hi. This is Ava from Vanta. In today's digital world, compliance regulations are changing constantly, and earning customer trust has never mattered more. Vanta helps companies get compliant, fast, and stay secure with the most advanced AI automation and continuous monitoring out there. So whether you're a start-up going for your first SOC 2 or ISO 27001, we are growing enterprise managing vendor risk. Vanta makes it quick, easy, and scalable. I'm not just saying that because I work here. Get started today at vanta.com.

Tim Beyers: All right, Fools, let's talk about Intel and NVIDIA. NVIDIA is investing $5 billion in Intel stock at $23.28 a share. This is a private placement, and the difference between investing on the open market and a private placement is that Intel is selling stock directly to NVIDIA, and thus they are getting the $5 billion to put on their balance sheet and deploy as capital for growing their business. It's a real interesting when the deal between the two will include work on both data center and personal computing products. I have a take on this, but I would like to go to you first. Here's Sanmeet, at the highest level, hearing that Intel and NVIDIA are going to work both in the data center and on personal computing products, what is your reaction?

Sanmeet Deo: I mean, I think it's great. I think they're both really helping each other out. You know Intel has a lot of the infrastructure and the facilities to create the chips that go into CPUs. That's not something NVIDIA has been an expert in. They're experts in the GPU sets. So being able to co design products when it comes to data center and the PCs is going to be helpful for both of them. So they're helping each other out.

Tim Beyers: I mean, Alicia, where do you stand on this? Because I mean, Sanmeet's right. NVIDIA doesn't necessarily have expertise making and we can talk a little bit more about this. I'll explain the details, but central processing units, which are kind of like, in the picture of an orchestra, if the GPUs is the great sound system, the CPU is the conductor at the front of the orchestra that makes all the sound come together, and then the sound system amplifies that. I mean, how do you feel about this deal?

Alicia Alfiere: Yeah, well, I'm going to say, I think that NVIDIA actually benefits more. Certainly the cash infusion and the product partnerships help Intel, but NVIDIA is the one with all of the power in this relationship, and now they get a stake in a partner as well. Also, I think for me to really call this in favor of Intel, I think I would need it to really benefit their foundry business. That's just my take. [laughs] But what do you think?

Tim Beyers: No, I think that's fair. I mean, and for those who don't know, so Intel is competing with Taiwan Semiconductor to take other people's designs and manufacture those chips. They have really not done a great job of scaling that business. Taiwan Semi is far and away the dominant provider in this part of the business. So that's a real question. Like, does that $5 billion go into building out the foundry business, so we actually manufacture more chips on American shores? We know that's something this administration wants. But for me, I look at this and see what Sanmeet said about NVIDIA getting into the CPU business through the back door is pretty interesting because NVIDIA does want to sell whole systems, particularly at Data Center scale. In order to sell whole systems, you do have to have again, no such thing as an orchestra if you don't have an orchestrator, if you don't have a conductor and you need that CPU. So I do think that is meaningful for NVIDIA, but I also think you're right about this like, who has the power in this relationship? I think we know. It's the one with the big checkbook. We know who has the power in this relationship. So for me, I do think it's a bigger deal for Intel in terms of potential value creation. But in terms of strategic fit, there's a lot to like about this from NVIDIA's perspective. But if I'm going to make a buy call, just based solely on this deal, this is not make me want to buy NVIDIA more, but it might make me want to at least move Intel onto the watch list. That is in some ways a reflection of the valuation Delta between the two. Up next, a bit of reflections on Rule Breaker Investing and David Gardner's new book.

All right, Fools, if you haven't seen it yet, last week, David Gardner, our co founder at The Motley Fool, our chief Rule Breaker released a new book which he is calling Rule Breaker Investing. You may have seen the iconic green cover already. It looks great. It is a reflection of the principles of Rule Breaker Investing along three different areas, the habits of a Rule Breaker Investor, the six traits of a rule breaking stock, and then the elements of rule breaking portfolio management. It's a very comprehensive book. It includes all of the learnings that David has had over like 30 years plus of investing at The Motley Fool and even before that and actually building out his Rule Breakers philosophy. We're each going to give a little bit of a story about how that philosophy has impacted us. I think, Alicia, I wouldn't mind starting with you. How do you think about Rule Breakers Investing the philosophy and what David's captured in this book?

Alicia Alfiere: Yeah, I think for me, the part of our ethos that I've really keyed in on over the last few years, I did start during the height of the pandemic bubble.

Tim Beyers: Yeah, I remember.

Alicia Alfiere: [laughs] Right. I think the part that I've really keyed on as a result is the overvalued by financial media part. It's important to realize that it's more than just picking a company that's price to perfection or price beyond perfection and thinking, hey, you only live once. It's about finding compelling companies and those that have price dislocation. What I mean by that is a company that might be misunderstood by the market has some optionality that is coming in the future that maybe the market is missing or is not giving ample credit to or has a short term challenge, also known as dark clouds that we can see through. I think for me, that's really been where the beauty is in working through Rule Breakers.

Tim Beyers: I like it. Sanmeet, how about yourself?

Sanmeet Deo: You know, so I think the Rule Breakers, I've worked on Wall Street, and so I've been exposed to value investing and growth investing. As you start investing and learning on your own, you fall into the strategy that works best for your own personality. Rule Breakers seems to really fit my personality and my style because a couple of the signs is consumer appeal and overvalued, the companies I really like and enjoy researching, picking, tend to fall into those two brackets. I mean, when you have a Netflix and a Chipotle and all these companies that have such strong consumer appeal, you see them every day. I find Rule Breaking Investing to be observational investing. You're looking around in the world, seeing what's happening and seeing if that's an investment opportunity. But these stocks don't tend to be very cheaply valued for a reason. This strategy kind of says, Hey, it's OK to buy overvalued stocks. Why are they overvalued? Because they're winning, and you want to buy more of these winners as they grow and as they continue to make an impact in the world. That's one of the most appealing parts about Rule Breaker Investing that I have adopted.

Tim Beyers: I like it. Well, I'll just close this out here and say I've spent the last 20 plus years learning to become a better investor as a member of the Rule Breakers team. I started on the Rule Breakers team in April 2005. Rule Breakers started in October of 2004. So we are about to hit 21 years. I mean, it's bonkers. I can barely believe it. Working with David, Rick, Carl, you, Alicia, Tom, so many others, it's been the greatest privilege of my professional life, to be sure. As I've grown in the role, David has helped me to see how my own expertise and insights could be honed through the lens of making my portfolio reflect my best vision for the world, which to this day remains one of the most important principles of Rule Breaker Investing. It's something David talks about extensively in the book, and it certainly led me to focusing on the most painful problems I could find. I'm a tech investor, so I tend to look for painful tech problems and then investing in the ones that are providing relief. I have to tell you that life changing returns I've achieved as a result of that, are a gift that I will never be able to fully repay to David. I'm very grateful for this book. It's been a great ride, and two decades on, I'm still getting smarter, happier, and richer, not every day. Maybe two out of three, most days. I'm not getting richer every single day. That is not true. The market does not cooperate in that way, but it's been a great ride, and I'm very grateful for David. I'm very grateful for the book. I'm grateful for Tom and David starting the Motley Fool. I've learned a lot. I mean, one of these days, we're going to do a tribute to Tom Gardner, too, and it's going to be just as eloquent because he's been just as important to the growth and development of the Motley Fool. I mean, the two of them together have just been unstoppable, and it's been great.

Enough with heaping on the praise for our bosses. But we do love them because they have been really great to us, and Rule Breaker Investing really has been a gift to us here. Who are employees of the Motley Fool who have worked closely with both Tom and David, and now David's released his book into the world. It can be something that benefits you. So we hope you give it a read. Pick it up, give it a read. I think it's worth your time. But that's it for today's show. Thank you for tuning in to Motley Fool Money. As always, people on the program may have interest in the stocks they talk about. The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear all personal finance content, follows Motley Fool editorial standards and is not approved by advertisers. Advertisements are sponsored content and provided for informational purposes only. To see our full advertising disclosure, please check out our show notes. For Alicia Alfiere, Sanmeet Deo, for our engineer, Dan Boyd and our producer, Anand Chokkavelu, I'm Tim Byers. Thank you for tuning in Fools. We will see you again tomorrow when Emily is going to be talking some small caps, and you're going to want to pay attention to that. So stay tuned. We'll see you again, Fools. Fool on.

Alicia Alfiere has positions in Apple. Sanmeet Deo has positions in Chipotle Mexican Grill, Hims & Hers Health, and Netflix. Tim Beyers has positions in Apple, Chipotle Mexican Grill, Netflix, Progyny, and Taiwan Semiconductor Manufacturing. The Motley Fool has positions in and recommends Apple, Chipotle Mexican Grill, Hims & Hers Health, Intel, Netflix, Nvidia, Progyny, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends the following options: short November 2025 $21 puts on Intel and short September 2025 $60 calls on Chipotle Mexican Grill. The Motley Fool has a disclosure policy.